	CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC), located in Seoul, South Korea. The purpose of the Memorandum is to affirm both CTI's and SMC's commitment to identifying and developing opportunities for cooperation and collaboration in advancing clinical research in fields such as rare and orphan disease, regenerative medicine, and hematology/oncology. The Memorandum was signed by Patrick J. Earley, CTI's Chief International Business Officer and Ki Woong Sung, Director of Clinical Research Institute at SMC.

	"We are thrilled to enter this strategic partnership with Samsung Medical Center," remarks Patrick J. Earley. "Samsung Medical Center is an innovative research site that is committed to bringing life-changing drugs to patients in need, just as CTI is. We have been working throughout the Asia-Pacific region for nearly a decade, and we have many successful collaborations throughout the region with leading academic centers and emerging biotechnology companies. CTI continues to grow steadily in the region, and we look forward to future accomplishments/efficiencies enabled by this partnership."